A new study suggests that GLP-1 receptor agonist medications, commonly used for weight loss and diabetes management, may be associated with lower cancer risk for certain malignancies. The research examined data across 13 different cancer types to identify potential protective effects. The findings add to growing evidence about the broader health impacts of GLP-1 drugs beyond their primary uses. Further research is needed to confirm these associations and understand the underlying mechanisms.
Weight & Metabolism · Jun 18, 2026 · 6 days ago
New Study Links GLP-1 Drugs to Reduced Risk of 13 Cancers
Read the full story at mindbodygreen.com →
This summary was prepared by the HealthyFreePress editorial desk; the underlying reporting belongs to the linked publisher. Nothing here is medical advice — see our Medical Disclaimer and Editorial Policy.